Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

NCT07424547 is registered in ClinicalTrials.gov with Conjupro Biotherapeutics, Inc. as lead sponsor.

NCT NCT07424547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07424547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Lead sponsor
Conjupro Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 3, 2026
Completion date
April 30, 2030
Enrollment
386 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced metastatic cancer, breast cancer, cancer, ovarian cancer, prostate, small cell lung cancer, solid tumor cancer